SCHEMBL20028489

SCHEMBL20028489

Cn1cc(C(=O)NC(Cc2ccccc2)C(=O)C(N)=O)c(-c2ccc3c(c2)OCO3)n1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 15/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPT P10636 1/20 0.48
DCAF1 Q9Y4B6 1/20 0.47
ITGB1 P05556 1/20 0.47
ITGA4 P13612 1/20 0.47
ITGB7 P26010 1/20 0.47
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
CTSS P25774 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30133684 1.00 CAPN1 (0.50) CAPN1ALDH1A1MAPTDCAF1ITGB1
SCHEMBL20027895 0.93 ALDH1A1 (0.51) CAPN1ALDH1A1MAPTDCAF1LMNA
SCHEMBL30133555 0.93 ALDH1A1 (0.51) CAPN1ALDH1A1MAPTDCAF1LMNA
SCHEMBL30133617 0.86 CAPN1 (0.47) CAPN1DCAF1
SCHEMBL20028005 0.86 CAPN1 (0.47) CAPN1DCAF1
SCHEMBL23268990 0.86 CAPN1 (0.59) CAPN1DCAF1CTSS
SCHEMBL20028632 0.86 CAPN1 (0.59) CAPN1DCAF1CTSS
SCHEMBL20028411 0.84 CAPN1 (0.55) CAPN1DCAF1
SCHEMBL21854255 0.84 DCAF1 (0.62) CAPN1ALDH1A1MAPTDCAF1CTSS
SCHEMBL20028618 0.84 DCAF1 (0.62) CAPN1ALDH1A1MAPTDCAF1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2020-04-23 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 CAPN1 3/4885ALDH1A1 4193/4885MAPT 562/4885
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885ALDH1A1 4193/4885MAPT 562/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 CAPN1 4/4885ALDH1A1 4421/4885MAPT 330/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885ALDH1A1 4193/4885MAPT 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.